Slide 1: Letter to National Stock Exchange of India
Date: 16.05.2026 To National Stock Exchange of India Limited ‘Exchange Plaza’, Bandra-Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ACCENTMIC ISIN: INE0Q5D01013 Sub : Investor presentation for the Half year and Year ended 31st March 2026 Pursuant to the requirements of Regulation 30 of th
Slide 2: Accent Microcell Limited Investor Presentation 2026
ACCENT MICROCELL LIMITED INVESTOR PRESENTATION 2026
Slide 3: Accent at a Glance
ACCENT AT A GLANCE Incorporated in 2012 and listed on NSE SME (2023) KEY METRICS Manufacturer of pharmaceutical excipients with focus on cellulose-based products Core portfolio includes Microcrystalline Cellulose (MCC), 2 9,200+ MTPA 75+ Countries 15+ SMCC, CCS & Magnesium Stearate Manufacturing Ins
Slide 4: Our Journey
OUR JOURNEY Established global Added other Achieved Economic Established as a presence excipients to the MCG grade Partnership Firm portfolio 2008 2006 2005 2001 Installed metal Established new Converted to Private Set up Microbial Lab Expanded globally detector at Dahej plant at Dahej Limited meeti
Slide 5: Our Certificates
OUR CERTIFICATES sce 3G 54g —__ HALAL CERTIFICATE 150 9001-2015
Slide 6: Product Portfolio
PRODUCT PORTFOLIO Microcrystalline Silicified Microcrystalline Microcrystalline MCC Spheres Cellulose (MCC) Cellulose (SMCC) Cellulose with CMC Inert carriers for APIs and (Co-processed) Multiple grades (Accel 101, 102, Enhanced flow, binding, and nutraceuticals for targeted drug 105, etc.) compacti
Slide 7: Industries We Serve
INDUSTRIES WE SERVE Pharmaceutical and Nutraceutical Food, Bakery & Dairy Companies Cosmeceuticals & Welding Electrodes Personal Care
Slide 8: Our Global Presence
OUR GLOBAL PRESENCE 17+ years of demonstrated experience in exports coupled with superior quality 22,086.80 Lakhs (63.28%) of the Company’s Revenue comes from exports. 12,816.48 Lakhs (36.72%) of the Company’s Revenue comes from domestic markets.
Slide 9: Industry Overview
INDUSTRY OVERVIEW Pharmaceutical Excipients & MCC Industry GLOBAL PHARMACEUTICAL EXCIPIENTS INDUSTRY CAGR: ~6.1% Oral solid dosage Pharmaceuticals = Shift toward specialty & dominates drug delivery largest end-use segment multifunctional excipients Tablets & capsules Excipients are critical for High
Slide 10: Industry Overview
INDUSTRY OVERVIEW Pharmaceutical Excipients & MCC Industry INDIAN PHARMACEUTICAL & MCC OPPORTUNITY Exports: USD 30+ Billion India as a global Import substitution China+1 sourcing (FY25) manufacturing hub opportunity in excipients shift Strong demand for export- Large-scale formulation Premium grades
Slide 11: Manufacturing Facility
MANUFACTURING FACILITY Pirana (Ahmedabad) – Unit I Key Highlights Product Flexibility & Efficiency & Quality Commitment: Installed Capacity: 2,000 MTPA Customer-Centric Approach Capacity Utilisation: 100% Latest technology & custom-engineered Area: 3,900.33 sq. mtrs. Multiple grade options backed by
Slide 12: Key Business Highlights
KEY BUSINESS HIGHLIGHTS Expanded & Diversified Operational & Product Portfolio Manufacturing Excellence Broadened offerings across multiple categories, catering Achieved high efficiency through process optimization, to varied industry needs with innovative and high- advanced technologies, and contin
Slide 13: Investment Highlights
INVESTMENT HIGHLIGHTS Strong Revenue Potential Capacity Expansion Projected ₹70 crore revenue in Year 1 Total installed capacity scaling from 9,200 MTPA Revenue mix: 60% exports | 40% domestic sales → 12,000 MTPA Margin-accretive product mix strengthening overall A ~30% capacity boost positioning th
Slide 14: Roadmap to Future Growth
ROADMAP TO FUTURE GROWTH Targeted Customer Segments for Deeper Focus on Value Added Market Penetration Expanding Applications Products Across Diverse Segments Pharmaceutical Companies Strategic emphasis on high-margin, differentiated Nutraceutical Companies offerings to boost profitability and stren
Slide 15: Our Promoter
OUR PROMOTER Mr. Vasant Vadilal Patel Mr. Ghanshyam Arjanbhai Patel Chairman Managing Director & CFO He brings 21+ years of higher experience in the dyes, He has 21+ years of higher experience in marketing across pharmaceuticals, and nutraceuticals industries. He has various sectors, including agro-
Slide 16: Revenue Breakup
REVENUE BREAKUP International Sales Domestic Sales Premium Products Non-Premium Products 100 100 80 80 36.72% 46.51% 60 60 96.26% 86.88% 40 40 20 20 53.49% 63.28% 13.12% 3.74% 0 0 FY 24-25 FY 25-26 FY 24-25 FY 25-26
Slide 17: Financial Analysis
FINANCIAL ANALYSIS Rs. In Lakhs REVENUE FROM OPERATIONS EBITDA RATIOS Interest coverage FY 25 FY 26 FY 25 FY 26 108.87x 26,457.69 34,903.28 4,831.77 6,345.83 YoY% | 31.92% YoY% | 31.34% PAT PAT MARGIN ROCE 25.01% FY 25 FY 26 FY 25 FY 26 ROE 3,306.29 4,385.85 12.50% 12.57% 18.65% YoY% | 32.65% YoY% |
Slide 18: Profit & Loss Statement
PROFIT & LOSS STATEMENT Rs. In Lakhs Particulars FY26 FY25 YoY% H2FY26 H1FY26 H2FY25 YoY% Revenue from Operations 34,903.28 26,457.69 31.92% 20,966.58 13,936.70 13,854.01 51.34% Other Income 676.67 640.86 5.59% 416.66 260.01 343.52 21.29% Total Income 35,579.95 27,098.55 31.30% 21,383.24 14,196.71 1
Slide 19: Balance Sheet
BALANCE SHEET Rs. In Lakhs Particulars 31st March, 2026 31st March, 2025 Share Capital 2,398.90 2,104.30 Reserves and Surplus 25,149.56 17,374.97 Trade Payables 755.36 294.12 Other Liabilities 3,866.88 3,064.05 Total Liabilities 32,170.70 22,837.44 Fixed Assets 15,607.80 6,232.48 Loans & Advances 2,
Slide 20: Disclaimer
DISCLAIMER This presentation and the accompanying slides (the "Presentation"), which have been prepared by Accent Microcell Limited (the "Company'), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 21: Thank You
THANK YOU 314, Shangrilla Arcade, Shyamal Cross Roads, Abhishek Bhutra | Himanshu Jain Anand Nagar Road, Satellite, +91 80006 85556, +91 89051 81853 Ahmedabad – 380015 Gujarat – INDIA. ir@finportalin.com inv_rel@accentmicrocell.com